These studies have been complemented by a clear demonstration of therapeutic efficacy by the former formulation against different sub-types of nucleolin-overexpressing mesothelioma orthotopic tumors, relative to the standard of care, while presenting a safe profile, including hematological and clinical chemistry parameters as assessed in rats and dogs and in comparison with a non-targeted formulation [19]. The gene discussed is NUCLEOLIN; the disease is mesothelioma.